Baili Tianheng announced that the company's partner BMS received a notice from the FDA that the BL-B01d1 combined drug project for phase 1/2a clinical trial application for the treatment of advanced solid tumors has been approved by the FDA. BL-B01D1 is the world's first dual-antibody ADC targeting EGFR×HER3. The company and BMS reached an exclusive license and cooperation agreement for this project. This license will further advance the process of internationalization of the company's business and products, and is expected to have a positive impact on the company's long-term business performance. However, the drug has a long cycle and many steps from early research to marketing. There are uncertainties. Investors need to make careful decisions and be careful to prevent investment risks.

Baili Tianheng announced that the company's partner BMS received a notice from the FDA that the BL-B01d1 combined drug project for phase 1/2a clinical trial application for the treatment of advanced solid tumors has been approved by the FDA. BL-B01D1 is the world's first dual-antibody ADC targeting EGFR×HER3. The company and BMS reached an exclusive license and cooperation agreement for this project. This license will further advance the process of internationalization of the company's business and products, and is expected to have a positive impact on the company's long-term business performance. However, the drug has a long cycle and many steps from early research to marketing. There are uncertainties. Investors need to make careful decisions and be careful to prevent investment risks.